Severe community-acquired pneumonia in ICUs: Prospective validation of a prognostic score

Objective To determine predictors of intensive care unit (ICU) mortality in patients with community-acquired pneumonia (CAP), to develop a pneumonia-specific prognostic index, and to evaluate this index prospectively.Design Combined retrospective and prospective clinical study over two periods: January 1987–December 1992 and January 1993–December 1994.Setting Four medical ICUs in the north of France.Patients Derivation cohort: 335 patients admitted to one ICU were retrospectively studied to determine prognosis factors and to develop a pneumonia-specific prognostic index. Validation cohort: 125 consecutive patients, admitted to four ICUs, were prospectively enrolled to evaluate this index.Results In the derivation cohort, 16 predictors of mortality were identified and assigned a value directly proportional to their magnitude in the mortality model: aspiration pneumonia (–0.37), grading of sepsis 11 (–0.2), antimicrobial combination (–0.01), Glasgow score >12+mechanical ventilation (MV) (+0.09), serum creatinine 15 mg/l (+0.22), chest involvement shown by X-ray 3 lobes (+0.28), shock (+0.29), bacteremia (+0.29), initial MV (+0.29), underlying ultimately or rapidly fatal illness (+0.31), Simplified Acute Physiology Score 12 (+0.49), neutrophil count 3500/mm³ (+0.52), acute organ system failure score 2 (+0.64), delayed MV (+0.67), immunosuppression (+1.38), and ineffective initial antimicrobial therapy (+1.5). An index was obtained by adding each patient's points. According to a receiver operating characteristic curve, the cut-off value of this index was 2.5. In the validation cohort, an index of 2.5 could predict death with a positive predictive value of 0.92, sensitivity 0.61, and specificity 0.98.Conclusion This index, which performs well in classifying patients at high-risk of death, may help physicians in initial patient care (appropriateness of the initial antimicrobial therapy) and guide future clinical research (analysis and design of therapeutic trials).